Perioperative chemotherapy strategies in diffuse gastric cancer

doi:10.4240/wjgs.v17.i1.101326

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (169)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

115

Sum=124

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=33

Jan 27, 2025 (publication date) through Jan 17, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Surg. Jan 27, 2025; 17(1): 101326
Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.101326

Perioperative chemotherapy strategies in diffuse gastric cancer

Niloufar Salehi, Maria Alqamish, Rasa Zarnegar

Niloufar Salehi, Maria Alqamish, Rasa Zarnegar, Department of Surgery, Division of Endocrine & Minimally Invasive Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10128, United States

Author contributions: Salehi N, Alqamish M, and Zarnegar R were involved in writing the paper and approved the final version.

Conflict-of-interest statement: Dr. Rasa Zarnegar works as a consultant for Intuitive, Medtronic, and Beckton-Dickenson. Drs. Niloufar Salehi and Maria Alqamish have no conflicts of interest or financial ties to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Rasa Zarnegar, FACS, MD, Professor, Department of Surgery, Division of Endocrine & Minimally Invasive Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, 525 E. 68^th Street, New York, NY 10128, United States. raz2002@med.cornell.edu

Received: September 14, 2024
Revised: November 22, 2024
Accepted: December 2, 2024
Published online: January 27, 2025
Processing time: 104 Days and 3.6 Hours

Abstract

This study reviews the findings of a recent study by Li et al, which demonstrated that perioperative chemotherapy benefits patients with diffuse-type gastric cancer compared to surgery alone. Despite potential biases, the study supports the inclusion of perioperative chemotherapy in treatment guidelines. Neoadjuvant and adjuvant chemotherapy may also provide similar survival outcomes, allowing for flexible treatment planning.

Keywords: Gastric cancer; Neoadjuvant chemotherapy; Adjuvant chemotherapy; Gastric adenocarcinoma; Survival

Core Tip: Perioperative chemotherapy is potentially effective for treating diffuse-type gastric cancer, supporting its continued inclusion in treatment guidelines. However, further research is needed to define optimal therapeutic strategies and improve patient outcomes.